Experimental NVG-291 Trial Restores Walking in Paralyzed Patient
A Fox News Digital report describes a U.S. phase 2 trial of NVG-291, an experimental injectable peptide, in which 58-year-old Pennsylvania participant Larry Williams regained measurable walking ability following three months of daily injections and therapy (April–July 2024). Lead researcher Dr. Monica Perez of the Shirley Ryan AbilityLab (Northwestern) is quoted about the trial; Williams reports lasting improvements more than a year after dosing, including faster 10‑meter walk times and brief free‑standing.
Health
Science
🔍 Key Facts
- NVG-291 is an experimental injectable peptide tested in a phase 2 trial in the U.S.
- Patient Larry Williams (58, Philadelphia) received daily injections April–July 2024 plus one hour of physical therapy per day
- Measured improvement: 10-meter walk time improved from 45 seconds to 15 seconds with a walker; patient reports continued gains >1 year after dosing